Royalty Pharma plc
RPRX
$45.12
$0.320.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.25% | -33.20% | 51.61% | 36.76% | -24.31% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 46.39% | 38.25% | 13.22% | 4.97% | -4.57% |
| Total Other Non-Cash Items | -44.04% | -16.27% | -92.73% | -47.92% | 16.59% |
| Change in Net Operating Assets | 9.91% | 6.62% | 8.36% | 9.70% | -5.30% |
| Cash from Operations | -10.08% | -14.07% | -9.85% | 3.12% | -7.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.51% | 62.25% | 41.08% | -30.40% | -29.20% |
| Cash from Investing | 39.73% | 59.91% | 38.03% | -30.40% | -29.20% |
| Total Debt Issued | 119.51% | 77.32% | -100.00% | 320.35% | 320.35% |
| Total Debt Repaid | -- | -550.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -434.46% | -478.76% | -359.42% | -207.93% | 24.65% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -0.47% | -1.46% | -2.30% | -3.99% | -5.06% |
| Other Financing Activities | -6.12% | -3.40% | -1.28% | -8.47% | -3.77% |
| Cash from Financing | -428.39% | -395.53% | -214.27% | 82.88% | 116.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -168.65% | -181.65% | -177.34% | 121.61% | 136.64% |